Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males

Journal of Lipid Research

Volumn 47, Issue 7, 2006, Pages 1366-1377

  Castellani, Lawrence W ^a   Chang, James J ^b   Wang, Xuping ^a   Lusis, Aldons J ^a   Reynolds, Wanda F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Atherosclerosis; Cholesterol; Hyperlipidemia; Macrophage; Myeloperoxidase; Triglycerides

Indexed keywords

CHOLESTEROL; GLUCOSE; MYELOPEROXIDASE; TRIACYLGLYCEROL;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HOMEOSTASIS; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; LIVER BLOOD VESSEL; MALE; MORBIDITY; MOUSE; NECROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALLELES; ANIMALS; ATHEROSCLEROSIS; DIETARY FATS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OBESITY; PEROXIDASE; PROMOTER REGIONS (GENETICS); RECEPTORS, LDL; RECOMBINANT PROTEINS; SEX CHARACTERISTICS;

EID: 33746081712     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600005-JLR200     Document Type: Article

References (43)

1. Podrez, E. A., M. Febbraio, N. Sheibani, D. Schmitt, R. L. Silverstein, D. P. Hajjar, P. A. Cohen, W. A. Frazier, H. F. Hoff, and S. L. Hazen. 2000. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105: 1095-1108.
2. Eiserich, J. P., M. Hristova, C. E. Cross, A. D. Jones, B. A. Freeman, B. Halliwell, and A. van der Vliet. 1998. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 391: 393-397.
3. Daugherty, A., J. L. Dunn, D. L. Rateri, and J. W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94: 437-444.
4. Hazen, S. L., J. R. Crowley, D. M. Mueller, and J. W. Heinecke. 1997. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase- catalyzed chlorination at sites of inflammation. Free Radic. Biol. Med. 23: 909-916.
5. Sugiyama, S., Y. Okada, G. K. Sukhova, R. Virmani, J. W. Heinecke, and P. Libby. 2001. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158: 879-891.
6. Bergt, C., S. Pennathur, X. Fu, J. Byun, K. O'Brien, T. O. McDonald, P. Singh, G. M. Anantharamaiah, A. Chait, J. Brunzell, et al. 2004. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA. 101: 13032-13037.
7. Zheng, L., B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114: 529-541.
8. Zhang, R., M. L. Brennan, X. Fu, R. J. Aviles, G. L. Pearce, M. S. Penn, E. J. Topol, D. L. Sprecher, and S. L. Hazen. 2001. Association between myeloperoxidase levels and risk of coronary artery disease. J. Am. Med. Assoc. 286: 2136-2142.
9. Brennan, M. L., M. S. Penn, F. Van Lente, V. Nambi, M. H. Shishehbor, R. J. Aviles, M. Goormastic, M. L. Pepoy, E. S. McErlean, E. J. Topol, et al. 2003. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349: 1595-1604.
10. Kutter, D., P. Devaquet, G. Vanderstocken, J. M. Paulus, V. Marchal, and A. Gothot. 2000. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 104: 10-15.
11. Piedrafita, F. J., R. B. Molander, G. Vansant, E. A. Orlova, M. Pfahl, and W. F. Reynolds. 1996. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J. Biol. Chem. 271: 14412-14420.
12. Kumar, A. P., F. J. Piedrafita, and W. F. Reynolds. 2004. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J. Biol. Chem. 279: 8300-8315.
13. Asselbergs, F. W., W. F. Reynolds, J. W. Cohen-Tervaert, G. A. Jessurun, and R. A. Tio. 2004. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am. J. Med. 116: 429-430.
14. Nikpoor, B., G. Turecki, C. Fournier, P. Theroux, and G. A. Rouleau. 2001. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am. Heart J. 142: 336-339.
15. Pecoits-Filho, R., P. Stenvinkel, A. Marchlewska, O. Heimburger, P. Barany, C. M. Hoff, C. J. Holmes, M. Suliman, B. Lindholm, M. Schalling, et al. 2003. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. Suppl. 84: 172-176.
16. Makela, R., R. Laaksonen, T. Janatuinen, R. Vesalainen, P. Nuutila, O. Jaakkola, J. Knuuti, and T. Lehtimaki. 2004. Myeloperoxidase gene variation and coronary flow reserve in young healthy men. J. Biomed. Sci. 11: 59-64.
17. Makela, R., P. J. Karhunen, T. A. Kunnas, E. Ilveskoski, O. A. Kajander, J. Mikkelsson, M. Perola, A. Penttila, and T. Lehtimaki. 2003. Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study. Lab. Invest. 83: 919-925.
18. Brennan, M. L., M. M. Anderson, D. M. Shih, X. D. Qu, X. Wang, A. C. Mehta, L. L. Lim, W. Shi, S. L. Hazen, J. S. Jacob, et al. 2001. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107: 419-430.
19. McMillen, T. S., J. W. Heinecke, and R. C. LeBoeuf. 2005. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation. 111: 2798-2804.
20. Reynolds, W. F., M. Hiltunen, M. Pirskanen, A. Mannermaa, S. Helisalmi, M. Lehtovirta, I. Alafuzoff, and H. Soininen. 2000. MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology. 55: 1284-1290.
21. Moore, K. J., E. D. Rosen, M. L. Fitzgerald, F. Randow, L. P. Andersson, D. Altshuler, D. S. Milstone, R. M. Mortensen, B. M. Spiegelman, and M. W. Freeman. 2001. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7: 41-47.
22. Chawla, A., W. A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak, S. B. Joseph, D. Liao, L. Nagy, P. A. Edwards, L. K. Curtiss, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7: 161-171.
23. Kumar, A. P., C. Ryan, V. Cordy, and W. F. Reynolds. 2005. Inducible nitric oxide synthase expression is inhibited by myeloperoxidase. Nitric Oxide. 13: 42-53.
24. Kumar, A. P., and W. F. Reynolds. 2005. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem. Biophys. Res. Commun. 331: 442-451.
25. Hoy, A., B. Leininger-Muller, O. Poirier, G. Siest, M. Gautier, A. Elbaz, P. Amarenco, and S. Visvikis. 2003. Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis. 167: 223-230.
26. Castellani, L. W., P. Gargalovic, M. Febbraio, S. Charugundla, M. L. Jien, and A. J. Lusis. 2004. Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II. J. Lipid Res. 45: 2377-2387.
27. Li, A. C., K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106: 523-531.
28. Carr, A. C., M. R. McCall, and B. Frei. 2000. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler. Thromb. Vasc. Biol. 20: 1716-1723.
29. Jolivalt, C., B. Leininger-Muller, R. Drozdz, J. W. Naskalski, and G. Siest. 1996. Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Neurosci. Lett. 210: 61-64.
30. Jolivalt, C., B. Leininger-Muller, P. Bertrand, R. Herber, Y. Christen, and G. Siest. 2000. Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic. Biol. Med. 28: 129-140.
31. Nagy, L., P. Tontonoz, J. G. Alvarez, H. Chen, and R. M. Evans. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93: 229-240.
32. Baker, P. R., Y. Lin, F. J. Schopfer, S. R. Woodcock, A. L. Groeger, C. Batthyany, S. Sweeney, M. H. Long, K. E. Iles, L. M. Baker, et al. 2005. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 280: 42464-42475.
33. Shi, W., M. E. Haberland, M. L. Jien, D. M. Shih, and A. J. Lusis. 2000. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation. 102: 75-81.
34. Lau, D., H. Mollnau, J. P. Eiserich, B. A. Freeman, A. Daiber, U. M. Gehling, J. Brummer, V. Rudolph, T. Munzel, T. Heitzer, et al. 2005. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. USA. 102: 431-436.
35. Baldus, S., J. P. Eiserich, A. Mani, L. Castro, M. Figueroa, P. Chumley, W. Ma, A. Tousson, C. R. White, D. C. Bullard, et al. 2001. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 108: 1759-1770.
36. Green, P. S., A. J. Mendez, J. S. Jacob, J. R. Crowley, W. Growdon, B. T. Hyman, and J. W. Heinecke. 2004. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 90: 724-733.
37. Choi, D. K., S. Pennathur, C. Perier, K. Tieu, P. Teismann, D. C. Wu, V. Jackson-Lewis, M. Vila, J. P. Vonsattel, J. W. Heinecke, et al. 2005. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 25: 6594-6600.
38. Leininger-Muller, B., A. Hoy, B. Herbeth, M. Pfister, J. M. Serot, M. Stavljenic-Rukavina, L. Massana, P. Passmore, G. Siest, and S. Visvikis. 2003. Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. Neurosci. Lett. 349: 95-98.
39. Reynolds, W. F., J. Rhees, D. Maciejewski, T. Paladino, H. Sieburg, R. A. Maki, and E. Masliah. 1999. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp. Neurol. 155: 31-41.
40. Reynolds, W. F., C. A. Stegeman, and J. W. Tervaert. 2002. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin. Immunol. 103: 154-160.
41. Schabath, M. B., M. R. Spitz, W. K. Hong, G. L. Delclos, W. F. Reynolds, G. B. Gunn, L. W. Whitehead, and X. Wu. 2002. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 37: 35-40.
42. Meisel, P., T. Krause, I. Cascorbi, W. Schroeder, F. Herrmann, U. John, and T. Kocher. 2002. Gender and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles. Genes Immun. 3: 102-106.
43. Hoy, A., D. Tregouet, B. Leininger-Muller, O. Poirier, M. Maurice, C. Sass, G. Siest, L. Tiret, and S. Visvikis. 2001. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur. J. Hum. Genet. 9: 780-786.